Ignite Creation Date:
2024-05-05 @ 10:57 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01223404
Status:
COMPLETED
Last Update Posted:
2019-08-19
First Post:
2010-10-13
Brief Title:
Nicotinic Modulation of the Default Network
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Nicotinic Modulation of the Default Network of Resting Brain Function
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Many disorders where attentional problems are a hallmark such as Alzheimers disease and schizophrenia display abnormal regulation of the so-called default network of resting brain function that maintains internally directed thought when the mind is free to wander There is indication that nicotine may improve attention by aiding the deactivation of the default network and this mechanism may be of therapeutic benefit for the above disease states The current project aims at providing a proof of concept by demonstrating that nicotinic drugs modulate default network function The nicotinic agonist nicotine is hypothesized to improve attention by facilitating the down-regulation of default network activity and the nicotinic antagonist mecamylamine is hypothesized to impair attention by impeding the down-regulation of default network activity during attentional task performance
Detailed Description:
This study only enrolls healthy non-smokers Participants perform attention tasks while undergoing functional Magnetic Resonance Imaging on three separate days Across the three days three difference conditions are tested in a double-blind manner in randomized order In all test sessions participants receive a skin patch and swallow a capsule In one session both are a placebo In another the patch is a low-dose nicotine patch and the capsule is a placebo In another session the patch is a placebo and the capsule contains a low dose of mecamylamine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R21DA027894 | NIH | None | httpsreporternihgovquickSearchR21DA027894 |